If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
<br /> HEMATOLOGY<br /> ISSN 2053-6631 July 2014 • emjreviews.com<br /> INSIDE<br /> Review of<br /> EHA 2014<br /> Milan, Italy<br /> Local Prescribing Information and full name<br /> and address of disclosing Takeda entity to<br /> be inserted according to local regulations<br /> ADCETRIS: DE<br /> INNOVATIVE CD30-TARGETED THERAPY<br /> Adcetris, a novel cd30-targeted antibody-drug conjugate, provides antitumour<br /> efficacy for relapsed or refractory Hodgkin lymphoma and sALcL patients5<br /> • For the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma:<br /> 1. following autologous stem cell transplant (ASCT) or<br /> 2. following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option<br /> • For the treatment of adult patients with relapsed or<a title="EMJ Hematology 2014 page 1" href="http://viewer.zmags.com/publication/3d823163?page=1"> HEMATOLOGY ISSN 2053-6631 </a> <a title="EMJ Hematology 2014 page 2" href="http://viewer.zmags.com/publication/3d823163?page=2"> Local Prescribing Information and full name and </a> <a title="EMJ Hematology 2014 page 3" href="http://viewer.zmags.com/publication/3d823163?page=3"> In relapsed or refractory Hodgkin lymphoma </a> <a title="EMJ Hematology 2014 page 4" href="http://viewer.zmags.com/publication/3d823163?page=4"> CONTENTS EDITORIAL BOARD.......................</a> <a title="EMJ Hematology 2014 page 5" href="http://viewer.zmags.com/publication/3d823163?page=5"> HEMATOLOGY AUTOLOGOUS STEM CELL TRANSPLANTATIO</a> <a title="EMJ Hematology 2014 page 6" href="http://viewer.zmags.com/publication/3d823163?page=6"> Editorial Board Hematology Editor-in-Chief: Pr</a> <a title="EMJ Hematology 2014 page 7" href="http://viewer.zmags.com/publication/3d823163?page=7"> Welcome Welcome to the European Medical Journal –</a> <a title="EMJ Hematology 2014 page 8" href="http://viewer.zmags.com/publication/3d823163?page=8"> SUBSCRIBE TO THE EMJ NEWSLETTER www.news.emjre</a> <a title="EMJ Hematology 2014 page 9" href="http://viewer.zmags.com/publication/3d823163?page=9"> Foreword Prof Emili Montserrat CLL and Lymphoma P</a> <a title="EMJ Hematology 2014 page 10" href="http://viewer.zmags.com/publication/3d823163?page=10"> EHA ANNUAL CONGRESS 2014 MICO MILANO CONGRESSI, M</a> <a title="EMJ Hematology 2014 page 11" href="http://viewer.zmags.com/publication/3d823163?page=11"> Welcome to the European Medical Journal review of</a> <a title="EMJ Hematology 2014 page 12" href="http://viewer.zmags.com/publication/3d823163?page=12"> EHA ANNUAL CONGRESS 2014 MICO MILANO CONGRESSI, M</a> <a title="EMJ Hematology 2014 page 13" href="http://viewer.zmags.com/publication/3d823163?page=13"> well as impressive response rates. In many ways t</a> <a title="EMJ Hematology 2014 page 14" href="http://viewer.zmags.com/publication/3d823163?page=14"> EHA ANNUAL CONGRESS 2014 MICO MILANO CONGRESSI, M</a> <a title="EMJ Hematology 2014 page 15" href="http://viewer.zmags.com/publication/3d823163?page=15"> Minimal residual disease will reside no longer </a> <a title="EMJ Hematology 2014 page 16" href="http://viewer.zmags.com/publication/3d823163?page=16"> EHA ANNUAL CONGRESS 2014 MICO MILANO CONGRESSI, M</a> <a title="EMJ Hematology 2014 page 17" href="http://viewer.zmags.com/publication/3d823163?page=17"> Defitelio® fighting severe hepatic veno-occlusive d</a> <a title="EMJ Hematology 2014 page 18" href="http://viewer.zmags.com/publication/3d823163?page=18"> EHA ANNUAL CONGRESS 2014 MICO MILANO CONGRESSI, M</a> <a title="EMJ Hematology 2014 page 19" href="http://viewer.zmags.com/publication/3d823163?page=19"> Velcade® reinforces its role as the backbone of m</a> <a title="EMJ Hematology 2014 page 20" href="http://viewer.zmags.com/publication/3d823163?page=20"> EHA ANNUAL CONGRESS 2014 MICO MILANO CONGRESSI, M</a> <a title="EMJ Hematology 2014 page 21" href="http://viewer.zmags.com/publication/3d823163?page=21"> Eltrombopag safe and successful for all ages Th</a> <a title="EMJ Hematology 2014 page 22" href="http://viewer.zmags.com/publication/3d823163?page=22"> EHA ANNUAL CONGRESS 2014 MICO MILANO CONGRESSI, M</a> <a title="EMJ Hematology 2014 page 23" href="http://viewer.zmags.com/publication/3d823163?page=23"> New drug multiplies survival chances for multiple</a> <a title="EMJ Hematology 2014 page 24" href="http://viewer.zmags.com/publication/3d823163?page=24"> EHA ANNUAL CONGRESS 2014 MICO MILANO CONGRESSI, M</a> <a title="EMJ Hematology 2014 page 25" href="http://viewer.zmags.com/publication/3d823163?page=25"> Mutation determining evolution of leukaemia MUTAT</a> <a title="EMJ Hematology 2014 page 26" href="http://viewer.zmags.com/publication/3d823163?page=26"> EHA ANNUAL CONGRESS 2014 MICO MILANO CONGRESSI, M</a> <a title="EMJ Hematology 2014 page 27" href="http://viewer.zmags.com/publication/3d823163?page=27"> Hematopoietic stem cell reprogramming: a vice ver</a> <a title="EMJ Hematology 2014 page 28" href="http://viewer.zmags.com/publication/3d823163?page=28"> EHA ANNUAL CONGRESS 2014 MICO MILANO CONGRESSI, M</a> <a title="EMJ Hematology 2014 page 29" href="http://viewer.zmags.com/publication/3d823163?page=29"> </a> <a title="EMJ Hematology 2014 page 30" href="http://viewer.zmags.com/publication/3d823163?page=30"> BIOSIMILARS IN HEMATOLOGY: INCREASING </a> <a title="EMJ Hematology 2014 page 31" href="http://viewer.zmags.com/publication/3d823163?page=31"> the development of biosimilars while Prof Steffen</a> <a title="EMJ Hematology 2014 page 32" href="http://viewer.zmags.com/publication/3d823163?page=32"> and, as with product purity, this can potentially</a> <a title="EMJ Hematology 2014 page 33" href="http://viewer.zmags.com/publication/3d823163?page=33"> Table 1: Proposal for a more precise terminology.</a> <a title="EMJ Hematology 2014 page 34" href="http://viewer.zmags.com/publication/3d823163?page=34"> All biologicals will regularly undergo manufactur</a> <a title="EMJ Hematology 2014 page 35" href="http://viewer.zmags.com/publication/3d823163?page=35"> will expire soon in both the EU and USA.2</a> <a title="EMJ Hematology 2014 page 36" href="http://viewer.zmags.com/publication/3d823163?page=36"> Moreover, deaths from cancer in the G7 countries </a> <a title="EMJ Hematology 2014 page 37" href="http://viewer.zmags.com/publication/3d823163?page=37"> the UK (Figure 2). This suggests that much of the</a> <a title="EMJ Hematology 2014 page 38" href="http://viewer.zmags.com/publication/3d823163?page=38"> 17. Lucio SD et al. Biosimilars: implications for</a> <a title="EMJ Hematology 2014 page 39" href="http://viewer.zmags.com/publication/3d823163?page=39"> use to reduce febrile neutropenia in patient</a> <a title="EMJ Hematology 2014 page 40" href="http://viewer.zmags.com/publication/3d823163?page=40"> NEXT STEPS IN FRONT-LINE TREATMENT OF </a> <a title="EMJ Hematology 2014 page 41" href="http://viewer.zmags.com/publication/3d823163?page=41"> Front-line Therapy for FL: a Shift towards C</a> <a title="EMJ Hematology 2014 page 42" href="http://viewer.zmags.com/publication/3d823163?page=42"> Table 1: Response rates of lenalidamide. All Pati</a> <a title="EMJ Hematology 2014 page 43" href="http://viewer.zmags.com/publication/3d823163?page=43"> can be performed in <36 hours, and is economicall</a> <a title="EMJ Hematology 2014 page 44" href="http://viewer.zmags.com/publication/3d823163?page=44"> Update on Current Trends in MCL Front</a> <a title="EMJ Hematology 2014 page 45" href="http://viewer.zmags.com/publication/3d823163?page=45"> <65 years MCL younger: R-CH</a> <a title="EMJ Hematology 2014 page 46" href="http://viewer.zmags.com/publication/3d823163?page=46"> Current problems with PTCL include the rarity of </a> <a title="EMJ Hematology 2014 page 47" href="http://viewer.zmags.com/publication/3d823163?page=47"> antibody) plus rituximab (CALGB 50402): Follicula</a> <a title="EMJ Hematology 2014 page 48" href="http://viewer.zmags.com/publication/3d823163?page=48"> Cancer. 2011;117:5058–66. 38. Yang Y et al. Explo</a> <a title="EMJ Hematology 2014 page 49" href="http://viewer.zmags.com/publication/3d823163?page=49"> lymphomas. J Clin Oncol. 2014;32:44–50. 70. Horwi</a> <a title="EMJ Hematology 2014 page 50" href="http://viewer.zmags.com/publication/3d823163?page=50"> THE MULTIPLE FACETS OF THROMBOTIC MICROANGIOPATHI</a> <a title="EMJ Hematology 2014 page 51" href="http://viewer.zmags.com/publication/3d823163?page=51"> a young girl who suddenly presented with fever, c</a> <a title="EMJ Hematology 2014 page 52" href="http://viewer.zmags.com/publication/3d823163?page=52"> The type of mutation impacts the prognosis of the</a> <a title="EMJ Hematology 2014 page 53" href="http://viewer.zmags.com/publication/3d823163?page=53"> aHUS and the Role of Complement Professor Javier </a> <a title="EMJ Hematology 2014 page 54" href="http://viewer.zmags.com/publication/3d823163?page=54"> In aHUS patients, once an environmental trigger i</a> <a title="EMJ Hematology 2014 page 55" href="http://viewer.zmags.com/publication/3d823163?page=55"> Management of HUS in 2014 Professor Thorsten Feld</a> <a title="EMJ Hematology 2014 page 56" href="http://viewer.zmags.com/publication/3d823163?page=56"> eGFR rate and CKD Stage. The improvements were no</a> <a title="EMJ Hematology 2014 page 57" href="http://viewer.zmags.com/publication/3d823163?page=57"> If eculizumab treatment is to be init</a> <a title="EMJ Hematology 2014 page 58" href="http://viewer.zmags.com/publication/3d823163?page=58"> 31. Licht C et al. Eculizumab (ECU) safety and ef</a> <a title="EMJ Hematology 2014 page 59" href="http://viewer.zmags.com/publication/3d823163?page=59"> Would you like to write for the EMJ blog? Intera</a> <a title="EMJ Hematology 2014 page 60" href="http://viewer.zmags.com/publication/3d823163?page=60"> SUBSCRIBE FREE TO OUR YOUTUBE CHANNEL www.youtube</a> <a title="EMJ Hematology 2014 page 61" href="http://viewer.zmags.com/publication/3d823163?page=61"> Bre wit Exclusive Interviews from the Europe</a> <a title="EMJ Hematology 2014 page 62" href="http://viewer.zmags.com/publication/3d823163?page=62"> THE STANDARD OF CARE IN RELAPSED REFRACTORY</a> <a title="EMJ Hematology 2014 page 63" href="http://viewer.zmags.com/publication/3d823163?page=63"> HL HL is a relatively common and highly curable B</a> <a title="EMJ Hematology 2014 page 64" href="http://viewer.zmags.com/publication/3d823163?page=64"> targeted apoptosis.21 MMAE has also been found to</a> <a title="EMJ Hematology 2014 page 65" href="http://viewer.zmags.com/publication/3d823163?page=65"> after ABVD and 15-20% after BEACOPPesc) will pres</a> <a title="EMJ Hematology 2014 page 66" href="http://viewer.zmags.com/publication/3d823163?page=66"> Relapsed or refractory HL Second-line chemother</a> <a title="EMJ Hematology 2014 page 67" href="http://viewer.zmags.com/publication/3d823163?page=67"> Management of relapsing or refractory sALCL To da</a> <a title="EMJ Hematology 2014 page 68" href="http://viewer.zmags.com/publication/3d823163?page=68"> REFERENCES 1. Falini B et al. CD30 (Ki-1) molecu</a> <a title="EMJ Hematology 2014 page 69" href="http://viewer.zmags.com/publication/3d823163?page=69"> 42. Nathwani N et al. Persistence of CD30 e</a> <a title="EMJ Hematology 2014 page 70" href="http://viewer.zmags.com/publication/3d823163?page=70"> OVERCOMING IMMUNODEFICIENCY IN CHRONIC LYMPHOC</a> <a title="EMJ Hematology 2014 page 71" href="http://viewer.zmags.com/publication/3d823163?page=71"> might overcome the issues associated wi</a> <a title="EMJ Hematology 2014 page 72" href="http://viewer.zmags.com/publication/3d823163?page=72"> have normal serum concentrations of man</a> <a title="EMJ Hematology 2014 page 73" href="http://viewer.zmags.com/publication/3d823163?page=73"> BCL-2 inhibitors sorafenib CLL cell Anti-ap</a> <a title="EMJ Hematology 2014 page 74" href="http://viewer.zmags.com/publication/3d823163?page=74"> with Clb alone. Treatment with Clb-O compared wit</a> <a title="EMJ Hematology 2014 page 75" href="http://viewer.zmags.com/publication/3d823163?page=75"> severe toxicities occurring in 40% and 35% </a> <a title="EMJ Hematology 2014 page 76" href="http://viewer.zmags.com/publication/3d823163?page=76"> REFERENCES 1. Chiorazzi N et al. Chronic lymphoc</a> <a title="EMJ Hematology 2014 page 77" href="http://viewer.zmags.com/publication/3d823163?page=77"> cells induce expression of B7/BB1 on normal </a> <a title="EMJ Hematology 2014 page 78" href="http://viewer.zmags.com/publication/3d823163?page=78"> directed T-cell motility by altering Rho GTPase s</a> <a title="EMJ Hematology 2014 page 79" href="http://viewer.zmags.com/publication/3d823163?page=79"> Transl Med. 2011;3(95):95ra73. </a> <a title="EMJ Hematology 2014 page 80" href="http://viewer.zmags.com/publication/3d823163?page=80"> THE ROLE OF CD49d IN CHRONIC LYMPHOCYTIC </a> <a title="EMJ Hematology 2014 page 81" href="http://viewer.zmags.com/publication/3d823163?page=81"> well as a mutated configuration of the TP53</a> <a title="EMJ Hematology 2014 page 82" href="http://viewer.zmags.com/publication/3d823163?page=82"> Adhesion of CLL cells via CD49d also upregulates </a> <a title="EMJ Hematology 2014 page 83" href="http://viewer.zmags.com/publication/3d823163?page=83"> inhibitor idelalisib,60 are promising alt</a> <a title="EMJ Hematology 2014 page 84" href="http://viewer.zmags.com/publication/3d823163?page=84"> ASSOCIATION OF CD49d WITH TRISOMY 12 In a recent</a> <a title="EMJ Hematology 2014 page 85" href="http://viewer.zmags.com/publication/3d823163?page=85"> stromal/endothelial cells MICROENVIRONMENT FIBR</a> <a title="EMJ Hematology 2014 page 86" href="http://viewer.zmags.com/publication/3d823163?page=86"> of novel gene mutations in poor- progno</a> <a title="EMJ Hematology 2014 page 87" href="http://viewer.zmags.com/publication/3d823163?page=87"> 45. Brachtl G et al. Differential bone marr</a> <a title="EMJ Hematology 2014 page 88" href="http://viewer.zmags.com/publication/3d823163?page=88"> CURRENT DEVELOPMENTS AND PERSPECTIVES </a> <a title="EMJ Hematology 2014 page 89" href="http://viewer.zmags.com/publication/3d823163?page=89"> ethnicity, with a 2-3-fold higher incidence </a> <a title="EMJ Hematology 2014 page 90" href="http://viewer.zmags.com/publication/3d823163?page=90"> observed with lenalidomide maintenance,35,37 whil</a> <a title="EMJ Hematology 2014 page 91" href="http://viewer.zmags.com/publication/3d823163?page=91"> 65 often present concurrent diseases, which </a> <a title="EMJ Hematology 2014 page 92" href="http://viewer.zmags.com/publication/3d823163?page=92"> and prednisone versus BTZ plus melphalan and pred</a> <a title="EMJ Hematology 2014 page 93" href="http://viewer.zmags.com/publication/3d823163?page=93"> Table 1 continued. Class Compound Study T</a> <a title="EMJ Hematology 2014 page 94" href="http://viewer.zmags.com/publication/3d823163?page=94"> Preliminary reported adverse events inclu</a> <a title="EMJ Hematology 2014 page 95" href="http://viewer.zmags.com/publication/3d823163?page=95"> also announced a high-priority Phase III registra</a> <a title="EMJ Hematology 2014 page 96" href="http://viewer.zmags.com/publication/3d823163?page=96"> 22. Hoering A et al. Complete remission in multip</a> <a title="EMJ Hematology 2014 page 97" href="http://viewer.zmags.com/publication/3d823163?page=97"> Clin Oncol. 2007;25(25):3892-901. 58. Kropff M </a> <a title="EMJ Hematology 2014 page 98" href="http://viewer.zmags.com/publication/3d823163?page=98"> MLN9708 against multiple myeloma cells. Clin Canc</a> <a title="EMJ Hematology 2014 page 99" href="http://viewer.zmags.com/publication/3d823163?page=99"> AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIP</a> <a title="EMJ Hematology 2014 page 100" href="http://viewer.zmags.com/publication/3d823163?page=100"> double ASCT is still matter of debate, from the l</a> <a title="EMJ Hematology 2014 page 101" href="http://viewer.zmags.com/publication/3d823163?page=101"> Table 1: Results obtained with novel drug combina</a> <a title="EMJ Hematology 2014 page 102" href="http://viewer.zmags.com/publication/3d823163?page=102"> Should ASCT be Performed Upfront or After First R</a> <a title="EMJ Hematology 2014 page 103" href="http://viewer.zmags.com/publication/3d823163?page=103"> or novel agents are presently proposed for high-r</a> <a title="EMJ Hematology 2014 page 104" href="http://viewer.zmags.com/publication/3d823163?page=104"> dexamethasone as induction before, and cons</a> <a title="EMJ Hematology 2014 page 105" href="http://viewer.zmags.com/publication/3d823163?page=105"> 57. Avet-Loiseau H et al. Long-term analysis</a> <a title="EMJ Hematology 2014 page 106" href="http://viewer.zmags.com/publication/3d823163?page=106"> THE ROLE OF JAK2 MUTATION IN THROMBOTI</a> <a title="EMJ Hematology 2014 page 107" href="http://viewer.zmags.com/publication/3d823163?page=107"> risk compared with JAK2 negative patients.7-</a> <a title="EMJ Hematology 2014 page 108" href="http://viewer.zmags.com/publication/3d823163?page=108"> Pathogenesis of thrombosis JAK2 mutation MPN pati</a> <a title="EMJ Hematology 2014 page 109" href="http://viewer.zmags.com/publication/3d823163?page=109"> chronic MPNs, but also in acute MPNs as well. Def</a> <a title="EMJ Hematology 2014 page 110" href="http://viewer.zmags.com/publication/3d823163?page=110"> of leuko-platelet aggregates CD11bCD4</a> <a title="EMJ Hematology 2014 page 111" href="http://viewer.zmags.com/publication/3d823163?page=111"> Selectins are also present on endothelial c</a> <a title="EMJ Hematology 2014 page 112" href="http://viewer.zmags.com/publication/3d823163?page=112"> REFERENCES 1. Falanga A, Marchetti M. Thrombotic</a> <a title="EMJ Hematology 2014 page 113" href="http://viewer.zmags.com/publication/3d823163?page=113"> thromboembolism and myeloproliferative neoplasms.</a> <a title="EMJ Hematology 2014 page 114" href="http://viewer.zmags.com/publication/3d823163?page=114"> CALRETICULIN IN MYELOPROLIFERATIVE NEOPLASMS: </a> <a title="EMJ Hematology 2014 page 115" href="http://viewer.zmags.com/publication/3d823163?page=115"> Ph-positive MPN that harbour one primary lesion, </a> <a title="EMJ Hematology 2014 page 116" href="http://viewer.zmags.com/publication/3d823163?page=116"> such as ruxolitinib, currently used to treat pati</a> <a title="EMJ Hematology 2014 page 117" href="http://viewer.zmags.com/publication/3d823163?page=117"> ND PV STAT5 G</a> <a title="EMJ Hematology 2014 page 118" href="http://viewer.zmags.com/publication/3d823163?page=118"> High affinity/ </a> <a title="EMJ Hematology 2014 page 119" href="http://viewer.zmags.com/publication/3d823163?page=119"> Nucleus GRα GRα P hsp90 G</a> <a title="EMJ Hematology 2014 page 120" href="http://viewer.zmags.com/publication/3d823163?page=120"> Epo-R JAK2 STAT5 GRα-STAT5 GRβ (JAK2-mutated</a> <a title="EMJ Hematology 2014 page 121" href="http://viewer.zmags.com/publication/3d823163?page=121"> that did not express GRβ but probably expressed t</a> <a title="EMJ Hematology 2014 page 122" href="http://viewer.zmags.com/publication/3d823163?page=122"> can be a late event in the progression of myelopr</a> <a title="EMJ Hematology 2014 page 123" href="http://viewer.zmags.com/publication/3d823163?page=123"> IRON SUPPLEMENTATION FOR PERIOPERATIVE ANAEMIA </a> <a title="EMJ Hematology 2014 page 124" href="http://viewer.zmags.com/publication/3d823163?page=124"> In this paper, we will review the diagnosis and t</a> <a title="EMJ Hematology 2014 page 125" href="http://viewer.zmags.com/publication/3d823163?page=125"> TSAT <20% ANAEMIA TSAT ≥20% Ferritin <30 μg/</a> <a title="EMJ Hematology 2014 page 126" href="http://viewer.zmags.com/publication/3d823163?page=126"> Table 1: Some characteristics of the different in</a> <a title="EMJ Hematology 2014 page 127" href="http://viewer.zmags.com/publication/3d823163?page=127"> Similarly, IV iron therapy is recommended f</a> <a title="EMJ Hematology 2014 page 128" href="http://viewer.zmags.com/publication/3d823163?page=128"> • All prescribers should inform patients of the r</a> <a title="EMJ Hematology 2014 page 129" href="http://viewer.zmags.com/publication/3d823163?page=129"> consumption or reducing tissue oxygen debt in sel</a> <a title="EMJ Hematology 2014 page 130" href="http://viewer.zmags.com/publication/3d823163?page=130"> REFERENCES 1. Leal-Noval SR et al. Spanish conse</a> <a title="EMJ Hematology 2014 page 131" href="http://viewer.zmags.com/publication/3d823163?page=131"> outcome in major orthopedic surgery: a pool</a> <a title="EMJ Hematology 2014 page 132" href="http://viewer.zmags.com/publication/3d823163?page=132"> 82. Carson JL et al. Transfusion thresholds and o</a> <a title="EMJ Hematology 2014 page 133" href="http://viewer.zmags.com/publication/3d823163?page=133"> LOOKING BACK TO OUR ROOTS: 80 YEARS</a> <a title="EMJ Hematology 2014 page 134" href="http://viewer.zmags.com/publication/3d823163?page=134"> history, Dr Wintrobe realised that he could never</a> <a title="EMJ Hematology 2014 page 135" href="http://viewer.zmags.com/publication/3d823163?page=135"> the width of the distribution.12 Other technologi</a> <a title="EMJ Hematology 2014 page 136" href="http://viewer.zmags.com/publication/3d823163?page=136"> In summary, technological advances be</a> <a title="EMJ Hematology 2014 page 137" href="http://viewer.zmags.com/publication/3d823163?page=137"> Am J Clin Pathol. 2008;130(1):104-16. 10. Lemelso</a> <a title="EMJ Hematology 2014 page 138" href="http://viewer.zmags.com/publication/3d823163?page=138"> WHAT’S NEW Leukaemia and Massive improvements and</a> <a title="EMJ Hematology 2014 page 139" href="http://viewer.zmags.com/publication/3d823163?page=139"> HEMATOLOGY Nose no bounds: pushing the boundaries</a> <a title="EMJ Hematology 2014 page 140" href="http://viewer.zmags.com/publication/3d823163?page=140"> WHAT’S NEW Mini heart pumping it up “We are s</a> <a title="EMJ Hematology 2014 page 141" href="http://viewer.zmags.com/publication/3d823163?page=141"> HEMATOLOGY Step aside stubborn blood cancer </a> <a title="EMJ Hematology 2014 page 142" href="http://viewer.zmags.com/publication/3d823163?page=142"> WHAT’S NEW The benefits Gen</a> <a title="EMJ Hematology 2014 page 143" href="http://viewer.zmags.com/publication/3d823163?page=143"> HEMATOLOGY Malaria hopes rekindled by spermicidal</a> <a title="EMJ Hematology 2014 page 144" href="http://viewer.zmags.com/publication/3d823163?page=144"> WHAT’S NEW Sticky cells, a living hell “</a> <a title="EMJ Hematology 2014 page 145" href="http://viewer.zmags.com/publication/3d823163?page=145"> From a host of fifteen therapeutic areas, EUROPEAN</a> <a title="EMJ Hematology 2014 page 146" href="http://viewer.zmags.com/publication/3d823163?page=146"> Featured Suppliers Hematology With its headqu</a> <a title="EMJ Hematology 2014 page 147" href="http://viewer.zmags.com/publication/3d823163?page=147"> Buyer’s Guide Exhibitors • ADAPTIVE BIOTECHNOL</a> <a title="EMJ Hematology 2014 page 148" href="http://viewer.zmags.com/publication/3d823163?page=148"> UPCOMING EVENTS 35th World Congress of the Inter</a> <a title="EMJ Hematology 2014 page 149" href="http://viewer.zmags.com/publication/3d823163?page=149"> HEMATOLOGY European School of Haematology (ESH) </a> <a title="EMJ Hematology 2014 page 150" href="http://viewer.zmags.com/publication/3d823163?page=150"> SUBSCRIBE TO RECEIVE THE LATEST C ATIONS</a>